Effective vaccination of cattle using the virion G protein of bovine ephemeral fever virus as an antigen

Uren, M. F.; Walker, Peter; Zakrzewski, H.; George, T. D. St.; Byrne, Keren

doi:10.1016/0264-410x(94)90295-x

Cited by 41 publications

(36 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Johal et al (2008) showed that the expressed BEFV glycoprotein G by recombinant baculoviruses reacted with BEFV-neutralising monoclonal antibodies (MAbs) to all continuous and conformational antigenic sites and may be a useful vaccine antigen. Vaccinated rabbits and cattle with recombinant vaccinia viruses expressing the glycoprotein G developed high level of antibodies which neutralised BEFV in either mammalian or insect cells (Uren et al, 1994;Hertig et al, 1996). In addition, neutralising G protein monoclonal antibodies injected intraperitoneally conferred passive protection against intracerebral infection of suckling mice (Cybinski et al, 1990).…”

Section: Discussionmentioning

confidence: 99%

“…Several researches have been directed towards the development of an efficient vaccine for BEF including live attenuated, inactivated, subunit G protein-based, and recombinant vaccines (Walker & Klement, 2015). The BEFV G glycoprotein is the target of virus neutralising antibodies (Cybinski et al, 1992;Uren et al, 1994). In addition, the highly protective characteristics of the native BEFV G protein suggest that its recombinant expressed product may be a useful vaccine antigen (Johal et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

“…In addition, the highly protective characteristics of the native BEFV G protein suggest that its recombinant expressed product may be a useful vaccine antigen (Johal et al, 2008). Accordingly, recombinant or DNA vaccine based on G protein may be an appropriate alternative for current vaccines (Uren et al, 1994). Because of a number of distinct advantages such as safety, stability, lower cost than some traditional vaccine types and longterm persistence of immunogenicity (Gurunathan et al, 2000), DNA vaccination can be an attractive approach to BEF vaccine development.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Expression of the G1 epitope of bovine ephemeral fever virus G glycoprotein in eukaryotic cells

Pasandideh¹,

Nassiri²,

Shapouri³

et al. 2018

BJVM

View full text Add to dashboard Cite

The envelope glycoprotein (protein G) of bovine ephemeral fever virus (BEFV) has been identified as a plausible vaccine candidate against the BEF disease. In the present study, G1 epitope of the G glycoprotein gene was cloned in an eukaryotic expression vector, pcDNA3.1(+), under the control of the human cytomegalovirus (CMV) promoter. The pcDNA3.1-G1 construct was transfected into human embryonic kidney 293 (HEK 293) cell line and the expression efficiency was verified by immunofluorescence staining of transfected cells and Western blot analysis. The results indicated that G1 protein was expressed by the recombinant pcDNA3.1-G1 construct in the transfected cells. The recombinant plasmid constructed in this study can be used as a DNA vaccine to evaluate its potential for immunogenicity and protection against BEF virus in animal models.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of the G1 epitope of bovine ephemeral fever virus G glycoprotein in eukaryotic cells

Pasandideh¹,

Nassiri²,

Shapouri³

et al. 2018

BJVM

View full text Add to dashboard Cite

show abstract

“…It has been reported that Quil A or Quil A combined with dextran sulphate may serve as better adjuvant than aluminum hydroxide gel for BEFV [20,21]. Vaccination of recombinant glycoprotein G with Quil A has been reported to induce protection against challenge [19]. Commercially available Al-gel vaccine with Tn73 strain is administered 3-4 times per year because it provides poor immune response [17].…”

Section: Discussionmentioning

confidence: 99%

DNA Sequence Analysis of Glycoprotein G Gene of Bovie Ephemeral Fever Virus and Development of a Double Oil Emulsion Vaccine against Bovine Ephemeral Fever

Hsieh

Wang²,

Lee

et al. 2006

J. Vet. Med. Sci.

View full text Add to dashboard Cite

ABSTRACT. The surface glycoprotein G is considered as the major neutralizing and protective antigen of bovine ephemeral fever virus (BEFV). Comparison of the deduced amino acid sequence of G protein of BEFV isolates during the period 1984-2004 outbreaks in Taiwan showed amino acid substitutions in the neutralizing epitopes. All the isolates differ markedly in the neutralizing epitope at the same amino acid positions compared to the currently available killed vaccine strain (Tn73). Tn88128 strain isolated in 1999 showed the maximum variability of 12 amino acids, 5 amino acid in the neutralization epitope and 7 apart from, respectively. Combinations of both Tn88128 (1999) and commercially available vaccine strain (Tn73) were developed and its safety was evaluated in mice, guinea pigs, calves, and pregnant cows. None of the animals showed any adverse effect or clinical signs. Calves were immunized with commercial vaccine (Tn73) and, combined vaccine (Tn73 and Tn88128), respectively, with adjuvants such as Al-gel and water-in-oil-in-water (w/o/ w) oil and PBS alone and challenged with Tn88128 strains. Except PBS administered animals, all the vaccinated animals showed protective immune response. However, animals immunized with combined vaccine plus w/o/w adjuvant elicited stronger neutralization antibodies and long lasting immunity compared to other vaccines. KEY WORDS: bovine ephemeral fever virus, genotyping, vaccine.

show abstract

“…The causative ephemerovirus is bullet-shaped and consists of a minus sense, single-stranded RNA genome; five structural proteins, including one surface glycoprotein (G); and no nonstructural proteins. The surface glycoprotein induces the production of a protective neutralizing antibody [5,15,16]. The disease is characterized clinically by the sudden onset of fever, stiffness, lameness, nasal and ocular discharges, depression, cessation of rumination, and constipation.…”

mentioning

confidence: 99%

Bovine Ephemeral Fever in Taiwan (2001-2002)

Hsieh

Chen

Chou

et al. 2005

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. Bovine ephemeral fever (BEF), a vector-borne disease of cattle, is caused by the Ephemerovirus of the family Rhabdoviridae. In the past 40 years, Taiwan has had seven BEF epizootics, and we have previously reported the first five. This study summarizes the 2001 and 2002 epizootics; conducted case-control serologic studies on 10 herds involved in the 2001 epizootic; determined whether the recent BEF viruses have varied significantly; and discusses the relationship between epizootic patterns and possible variant BEF viruses. For mature cows that had received at least 2 doses of vaccine before the study, a negative correlation between the prevaccinated (the 3rd dose and after) serum neutralization antibody (SNA) titers and their postvaccinated peak rates was found. When prevaccinated SNA levels were at ≤ 32, their postvaccinated SNA levels increased significantly faster (P<0.01) than for those at ≥ 32. The glycoprotein gene of isolates from 1999, 2001, and 2002 had a 99.2-99.9% homology, without consistent amino acid variations in the neutralization sites. Phylogenetic analysis of Taiwanese isolates revealed 2 distinct clusters, the 1983-1989 and 1996-2002 isolates. Cross-neutralization tests confirmed the glycoprotein gene sequence analysis results. In conclusion, annual boosters at SNA levels > 32, at more than 2 doses, or at intervals shorter than 6 months are not advisable. The occurrence of frequent small epizootics implies the dominance of BEF virus over host immunity, but not a variant virus. KEY WORDS: bovine ephemeral fever, outbreak, serology, vaccination.

show abstract

Effective vaccination of cattle using the virion G protein of bovine ephemeral fever virus as an antigen

Cited by 41 publications

References 25 publications

Expression of the G1 epitope of bovine ephemeral fever virus G glycoprotein in eukaryotic cells

Expression of the G1 epitope of bovine ephemeral fever virus G glycoprotein in eukaryotic cells

DNA Sequence Analysis of Glycoprotein G Gene of Bovie Ephemeral Fever Virus and Development of a Double Oil Emulsion Vaccine against Bovine Ephemeral Fever

Bovine Ephemeral Fever in Taiwan (2001-2002)

Contact Info

Product

Resources

About